A privately-owned clinical-stage biotech - having a facility in Switzerland (PS Biopharma AG), Immunophotonics has discovered (is developing) a novel and simple approach to achieve patient-specific anticancer immunity - a proprietary carbohydrate polymer designed to transform tumor ablation into hypnotherapy for cancer. The company's compound is intratumorally injected after a tumor ablation, utilizing the whole repertoire of tumor-associated neoantigens available in situ for the immune system after ablation-based immunogenic cell death, inducing a systemic anti-tumor immune response, enabling clinicians to treat late-stage metastatic cancers. Currently developing this asset - the immune-modulating proprietary carbohydrate polymer IP-001 for treatment of solid tumor cancers - has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.
